Bullfrog AI Holdings, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; comparisons are with fiscal 2022. The filing does not provide standalone fourth-quarter financial results. The company develops AI/ML analytics for drug development and pursues service contracts, collaborations, and licensed drug programs.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $65,000 | $10,000 |
| Gross profit / gross margin | $59,800 / approximately 92% | $9,200 / 92% |
| Research and development expense | $1,432,614 | $609,270 |
| General and administrative expense | $3,994,710 | $1,855,731 |
| Operating loss | $(5,367,524) | $(2,455,801) |
| Net loss | $(5,355,869) | $(2,802,487) |
| Operating cash flow | $(6,001,299) | $(910,890) |
| Cash and cash equivalents at year-end | $2,624,730 | $57,670 |
| Total current liabilities at year-end | $184,350 | $3,137,721 |
Revenue increased by $55,000 from a small base, while operating expenses rose $2.96 million. Management attributed higher R&D spending to staff and consulting costs, the J. Craig Venter Institute collaboration, a mebendazole-prodrug preclinical study, and additional JHU-APL technology access. Higher G&A reflected public-company costs, expanded staffing and consulting, investor relations and marketing, and recruiting.
Operating cash use increased substantially, in part because the company paid down accrued technology-access, consultant, and compensation costs. Financing activities provided $8.57 million, primarily from the IPO and warrant exercises. Year-end liabilities were $184,350, with no convertible notes outstanding; working capital was approximately $2.59 million. The company reported an accumulated deficit of approximately $9.75 million.
Material developments, outlook, and risks
- The February 2023 IPO generated approximately $7.3 million in net proceeds. In 2024, the company reported approximately $4.9 million of net proceeds from an offering and a further approximately $750,000 from the underwriters’ over-allotment.
- Management said available capital was expected to fund planned operations for more than 12 months from the filing date, even absent significant 2024 revenue. The 2024 financing is important to that liquidity assessment.
- The company reported its first commercial service contract in 2023 and has service contracts with two organizations, but revenue remains limited. It has not used its platform to produce a drug approved for commercialization and has not conducted its own pharmaceutical clinical trials.
- Drug programs remain at different early stages: the Beta2-spectrin siRNA program is preclinical; the licensed mebendazole formulation has prior Phase I trial data, but the company is planning further development; BF-223 showed positive results in a preclinical glioblastoma animal study. These findings do not establish clinical efficacy or regulatory approval.
- Management expects R&D and public-company costs to increase. The business depends on future financing, commercial adoption of its analytics, partnerships, and access to data, drug supply, and clinical-development partners. Drug development involves substantial expense, regulatory uncertainty, and the risk that candidates fail.
- The JHU-APL license includes royalties and minimum annual payments; the filing reports a $60,000 accrued 2023 minimum royalty. Additional license milestones, royalties, and sublicense terms may create future obligations.
- The auditor issued an unqualified opinion on the financial statements and identified going-concern evaluation as a critical audit matter. Management stated that the prior-year going-concern disclosure was no longer needed in light of financing and its plans. The company did not include management’s ICFR assessment because of a transition exemption, and the auditor did not provide an ICFR opinion.
- No material legal proceedings or off-balance-sheet arrangements were reported. The company said it had not experienced cybersecurity incidents that materially impaired operations or financial standing.
Key facts for investors to verify
- Whether post-year-end offering proceeds and current cash burn support management’s stated runway, and the assumptions behind that estimate.
- Whether service contracts convert into recurring, material revenue, and the economics of those contracts after royalties and delivery costs.
- Independent validation and reproducibility of bfLEAP results, including whether analytical findings lead to commercially valuable products or partnerships.
- Clinical, regulatory, and funding plans for the mebendazole, BF-223, and siRNA programs; distinguish prior third-party Phase I data and animal results from company-sponsored clinical evidence.
- Potential dilution from outstanding warrants, options, preferred stock, and the 2024 offering, alongside management’s actual financing needs.
- License obligations, including JHU-APL minimum royalties and the terms and milestones payable to university and research partners.